HomeNewsNeuroscienceMigraine

  • Novartis presents new Aimovig data to reinforce its efficacy, safety and tolerability

    • June 29, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • New Migraine study, by Novartis, indicates decreased workplace efficiency of patients

    • June 29, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Impel Neuropharma to present acute migraine treatment drug data at AHS 2018

    • June 28, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Lilly to present Galcanezumab and Lasmiditan Ph 3 data at AHS 2018

    • June 27, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Alder to present new data for Eptinezumab at American Headache Society Meeting

    • June 22, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Publication on novel Technology for Zolmitriptan in Migraine, announced by Zosano

    • June 22, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Teva discontinues Chronic Cluster Headache trial for Fremanezumab

    • June 18, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Prophylactic Migraine drug Atogepant displays positive efficacy and safety results in Ph 2b/3 trials

    • June 13, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Alder appoints new CEO to better prepare for Migraine drug launch

    • June 9, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Ph 3 data for Rimegepant in Acute Migraine to be presented at AHC annual scientific meeting 2018

    • June 6, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more